Literature DB >> 7578528

Rapid elimination of a high-titer spontaneous factor V antibody by extracorporeal antibody-based immunoadsorption and immunosuppression.

B Tribl1, P Knöbl, K Derfler, S Kapiotis, G Aspöck, U Jäger, W Hörl, K Lechner.   

Abstract

We report on the rapid elimination of a potent spontaneous factor V antibody of undetermined etiology by extracorporeal immunoadsorption on sepharose-bound polyclonal sheep antibodies to human immunoglobulins (Ig-Therasorb, Baxter) in combination with immunosuppressive treatment. A 68-year-old woman presented with severe hematuria. Severe factor V deficiency (< 1%) caused by an antibody to factor V (26 BU/ml) was found. Extracorporeal immunoadsorption (8.245 +/- 553 ml plasma processed per session) led to an average reduction of the antibody titer by 75% per session. The procedure was well tolerated without any side effects. Hematuria ceased after three immunoadsorptions and complete elimination of the antibody was achieved after seven sessions (day 15), followed by a rapid increase of the factor V activity to normal levels. Treatment with cyclophosphamide and prednisone was started on day 6 and continued for 2 months. The patient remains in remission at 6 months. Extracorporeal immunoadsorption is a highly effective method for eliminating antibodies to factor V (or other clotting factors) in selected cases, i.e., in patients with severe bleeding tendency, high antibody titer, and low probability of a rapid spontaneous remission.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7578528     DOI: 10.1007/BF01910319

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  44 in total

Review 1.  [Occurrence of a circulating anticoagulant, factor V inhibitor after surgical intervention].

Authors:  D Massignon; S Roullit; D Espinouse; P Coeur
Journal:  Ann Fr Anesth Reanim       Date:  1989

2.  Factor V inhibitor and bullous pemphigoid.

Authors:  K Bryning; J Leslie
Journal:  Br Med J       Date:  1977-09-10

3.  Massive hemorrhage associated with circulating antibodies to factor V.

Authors:  C A Onuora; J Lindenbaum; H L Nossel
Journal:  Am J Med Sci       Date:  1973-05       Impact factor: 2.378

4.  A circulating anticoagulant against factor V.

Authors:  I M Nilsson; U Hedner; M Ekberg; T Denneberg
Journal:  Acta Med Scand       Date:  1974 Jan-Feb

5.  Nature of the defect in congenital factor V deficiency: study in a patient with an acquired circulating anticoagulant.

Authors:  J C Fratantoni; M Hilgartner; R L Nachman
Journal:  Blood       Date:  1972-06       Impact factor: 22.113

6.  A specific inhibitor of human clotting factor V.

Authors:  V Lopez; R Pflugshaupt; R Bütler
Journal:  Acta Haematol       Date:  1968       Impact factor: 2.195

7.  Successful management of bleeding in a patient with factor V inhibitor by platelet transfusions.

Authors:  J Chediak; J B Ashenhurst; I Garlick; R K Desser
Journal:  Blood       Date:  1980-11       Impact factor: 22.113

8.  Factor V anticoagulants: clinical, biochemical, and immunological observations.

Authors:  D I Feinstein; S I Rapaport; W G McGehee; M J Patch
Journal:  J Clin Invest       Date:  1970-08       Impact factor: 14.808

9.  Immune complexes containing factor V in a patient with an acquired neutralizing antibody.

Authors:  H C Chiu; A K Rao; C Beckett; R W Colman
Journal:  Blood       Date:  1985-04       Impact factor: 22.113

10.  [Factor V inhibitor with double cancer].

Authors:  A Okajima; J Horii; K Nasu; Y Niki; K Akasaka; H Yamashita; M Sugimoto; A Yoshioka
Journal:  Rinsho Ketsueki       Date:  1989-04
View more
  3 in total

Review 1.  Acquired factor V inhibitors: a systematic review.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  J Thromb Thrombolysis       Date:  2011-05       Impact factor: 2.300

2.  IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study.

Authors:  G H Stummvoll; M Aringer; J S Smolen; S Schmaldienst; E Jiménez-Boj; W H Hörl; W B Graninger; K Derfler
Journal:  Ann Rheum Dis       Date:  2005-01-07       Impact factor: 19.103

3.  Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates.

Authors:  David Salas; Karin L Kwikkers; Nerea Zabaleta; Andrea Bazo; Harald Petry; Sander J van Deventer; Gloria Gonzalez Aseguinolaza; Valerie Ferreira
Journal:  Blood Adv       Date:  2019-09-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.